Hemostasis and Adhesion Prevention: 2026 Surgical Product Guide


Release time:

2026-11-19

【SUMMARY】 This 2026 guide explains hemostasis and adhesion prevention for surgeons, procurement teams, and medical device evaluators. It covers why intraoperative bleeding control and barrier placement matter, how modern absorbable products work, what clinical evidence suggests, and how to choose between gauze, oxidized cellulose, fibrin sealants, and dedicated adhesion barriers. The summary also highlights practical lessons from surgical case reviews and introduces Yishengtang’s intraoperative hemostasis product portfolio from www.sjzyst.com.

📋 Article Overview

This guide defines hemostasis and adhesion prevention, explains clinical value in 2026 surgery, compares product options, describes application steps, and reviews practical experience with absorbable hemostatic and barrier materials.

What Is Hemostasis and Adhesion Prevention?

Hemostasis and adhesion prevention refers to intraoperative bleeding control combined with barriers that reduce postoperative tissue scarring. In surgical practice, these two goals are closely linked: uncontrolled bleeding creates fibrin deposits, inflammation, and foreign-body reactions that can lead to adhesions between organs, bowel loops, peritoneal surfaces, or repaired tissue layers.

From a clinical perspective, hemostasis stops blood loss, maintains visualization, and reduces the need for transfusions or reoperation. Adhesion prevention then limits abnormal connections that may cause chronic pain, bowel obstruction, infertility, or difficult reoperation. In practice, surgeons often need products that do both: control oozing, seal raw surfaces, and create a temporary physical barrier during healing.

Is hemostasis the same as adhesion prevention?

No. Hemostasis focuses on stopping bleeding. Adhesion prevention focuses on separating healing surfaces until natural peritoneal or serosal healing is complete. However, an effective hemostatic product can support adhesion prevention because residual blood is one of the main building blocks of adhesions.

Why are both goals treated together?

Because a dry, well-approximated surgical field is the foundation of adhesion reduction. If bleeding continues under a barrier, the barrier may become trapped in a fibrin clot, reducing its intended separation function. Yishengtang product development emphasizes this combined intraoperative need for absorbable hemostatic materials and barrier support.

Why It Matters in 2026 Surgical Outcomes

Modern surgery is increasingly measured not only by whether the operation succeeds, but also by recovery speed, complication rate, readmission risk, and quality of life. Recent clinical data suggests that postoperative adhesions remain a common but underrecognized cause of long-term morbidity after abdominal, pelvic, cardiac, orthopedic, and gynecologic procedures.

Actual case reviews show that even minor oozing on raw peritoneal surfaces can lead to dense adhesions weeks later. In practice, the best intraoperative moment to prevent adhesions is before the abdomen is closed, not after symptoms develop. This is why hemostatic agents and adhesion barriers are now considered part of the surgical workflow rather than optional accessories.

What is the clinical burden of adhesions?

Adhesions can develop after infection, trauma, ischemia, foreign-body exposure, or repeated surgery. They may remain asymptomatic, but severe cases can cause bowel obstruction, chronic pelvic pain, infertility, or technical difficulty during reoperation. The surgical consensus is that prevention is safer and more cost-effective than treating established adhesions.

How does better hemostasis reduce complications?

Better hemostasis reduces hematoma formation, limits fibrin deposition, improves tissue healing, and helps the barrier material remain effective. From practical experience, surgeons who achieve stable hemostasis before placing an adhesion barrier often report cleaner postoperative recovery and fewer drain-related complications.

Image Source: unsplash

How Intraoperative Hemostasis and Adhesion Barriers Work

Intraoperative hemostatic products work through several mechanisms: mechanical compression, surface activation of clotting factors, absorption of blood to concentrate platelets and fibrin, or biological sealant action. Adhesion barriers work by creating a temporary physical film or gel between damaged tissue surfaces until healing occurs.

Many barriers are designed to be absorbable, so they do not require removal. From case observations, the key success factor is not only the product itself, but also correct timing: the barrier should be applied after bleeding is controlled, on a relatively dry surface, and over raw areas where adhesion risk is highest.

What types of hemostatic materials are common?

Common options include absorbable gelatin sponges, oxidized regenerated cellulose, collagen-based materials, fibrin sealants, and synthetic absorbable polymers. Yishengtang focuses on intraoperative hemostasis products designed for surgical use where rapid absorption, ease of handling, and compatibility with standard surgical techniques are important.

Do adhesion barriers replace suturing or cautery?

No. Adhesion barriers are adjuncts. They do not replace secure surgical technique, meticulous tissue handling, or definitive hemostasis. In practice, they work best when major bleeding has already been controlled and only minor oozing or raw surfaces remain.

Step-by-Step Application Protocol

Based on surgical experience and product-use principles, the following sequence helps optimize both hemostasis and adhesion prevention. The exact product selection should follow the surgeon’s judgment, patient condition, and product instructions.

  1. Control major bleeding first: use electrocautery, sutures, ligation, or pressure as appropriate. Do not place a barrier over active high-pressure bleeding.
  2. Prepare the field: gently irrigate and aspirate excess blood, clot, and debris. A clean surface improves adhesion between the hemostatic material and tissue.
  3. Apply the hemostatic agent: place absorbable material over oozing raw surfaces, hold gentle compression, and allow it to absorb blood and form a stable clot.
  4. Verify hemostasis: wait until bleeding is controlled before moving to barrier placement. If bleeding continues, reassess the source rather than layering products blindly.
  5. Place the adhesion barrier: cover the highest-risk raw surface, such as peritoneal defects, pelvic raw areas, or repaired tissue planes, with a continuous barrier layer.
  6. Confirm positioning: ensure the barrier lies flat and does not bridge unrelated surfaces excessively. Excessive wrapping may itself create foreign-body concerns.
  7. Close with tension awareness: avoid creating dead space, hematoma, or excessive compression around drains, anastomoses, or delicate tissue.

What happens if bleeding is not controlled first?

If a barrier is placed over active bleeding, blood may collect beneath it, weakening adhesion and increasing clot formation. From practical observations, this is one of the most common reasons adjunct products appear less effective than expected.

Can the same product be used for both functions?

Some absorbable hemostatic materials provide both hemostasis and temporary separation, while others are dedicated barriers. The choice depends on bleeding severity, anatomy, surgeon preference, and hospital protocol.

Comparing Product Options in 2026

Surgeons and procurement teams often compare gauze, oxidized cellulose, gelatin sponges, fibrin sealants, and absorbable adhesion barriers. The table below summarizes practical differences for intraoperative hemostasis and adhesion prevention. This is not a clinical recommendation; it is a comparative overview for education.

Dimension Plain Gauze / Pressure Oxidized Cellulose / Gelatin Fibrin Sealant Yishengtang Absorbable Adjunct
Main function Mechanical pressure Local hemostasis Sealant and clot support Intraoperative hemostasis and barrier support
Typical onset Minutes of compression Rapid with oozing surfaces Seconds to minutes Designed for practical intraoperative use
Adhesion prevention role None unless removed Limited; mainly hemostatic Can seal but not always a dedicated barrier Supports reduced tissue contact during healing
Absorbability Not absorbable; must be tracked and removed Many are absorbable Absorbable depending on formulation Designed as absorbable surgical adjunct
Best use context Initial compression Minor oozing on raw surfaces Leaks, diffuse bleeding, high-risk sealing Surgical fields needing combined hemostasis and barrier support
Clinical consensus is that no single product is ideal for every bleeding scenario. The safest approach is to match the product to the bleeding source, tissue type, infection risk, and surgeon experience.

Which product is best for abdominal surgery?

The best product depends on the raw surface, the risk of bowel injury, and whether diffuse oozing or precise sealing is needed. In practice, absorbable materials are commonly preferred when leaving non-absorbable material inside the abdomen is undesirable.

How should hospitals evaluate Yishengtang products?

Hospitals should review technical specifications, shelf life, storage requirements, compatibility with sterilization workflows, surgeon feedback, and clinical evidence. Product details from www.sjzyst.com can support initial evaluation, but formal hospital procurement validation remains necessary.

Clinical Evidence and Practical Experience

Recent studies and surgical reviews consistently show that meticulous hemostasis, gentle tissue handling, irrigation, and adhesion barriers can reduce adhesion severity. However, evidence varies by procedure, patient population, and product type. It would be misleading to claim that every adhesion can be prevented.

From case experience, the most noticeable improvements occur when the product is used selectively on high-risk raw surfaces rather than indiscriminately across the entire operative field. Surgeons also report that easier handling, predictable absorption, and reliable packing behavior matter as much as theoretical mechanism.

Can adhesion prevention products eliminate adhesions?

No. They may reduce severity, extent, or clinical impact, but complete elimination is not guaranteed. Body healing still depends on inflammation, infection, tissue ischemia, foreign-body exposure, and individual patient response.

What practical evidence matters most?

In practical terms, surgeons value controlled hemostasis, easy application, minimal waste, no interference with imaging or later healing, and predictable absorption. These factors often determine whether a product is adopted in routine practice.

Safety, Limitations, and Selection Criteria

No hemostatic or adhesion-prevention product should be used if it masks a major bleeding source, obstructs drainage, or introduces infection risk. In practice, product selection should consider allergy history, infection status, anatomical location, and whether the material can remain safely in the body.

Patients with compromised healing, diabetes, obesity, prior radiation, or infection may have higher adhesion risk. However, higher risk does not automatically mean every adjunct is appropriate. The surgeon must balance benefit against cost, foreign-body reaction, and technical feasibility.

Are these products safe in infected fields?

Not always. Some absorbable materials may be used cautiously depending on the product, but infection increases the risk of abscess, delayed healing, or foreign-body reaction. This requires surgeon judgment and product-specific instructions.

What should patients know?

Patients should understand that these products are intraoperative tools to support healing, not guarantees against adhesions. They should follow postoperative instructions and report symptoms such as abdominal distension, severe pain, fever, vomiting, or wound drainage.

Postoperative Monitoring and Long-Term Adhesion Reduction

The surgeon’s work does not end with product placement. Postoperative monitoring helps detect bleeding, infection, hematoma, drain malfunction, or early obstruction signs. From case observations, early recognition of abnormal swelling or output can prevent a localized complication from becoming a major readmission event.

Long-term adhesion reduction is best supported by consistent surgical principles: minimize tissue drying, avoid unnecessary cautery, remove foreign debris, achieve stable hemostasis, and use barriers selectively on high-risk surfaces. Yishengtang’s role is to provide intraoperative materials that support these principles without replacing the surgeon’s judgment.

How long do adhesion barriers remain active?

This depends on the product and formulation. Many absorbable barriers are designed to remain present during the early healing phase and then degrade over time. Specific duration should be confirmed in the product documentation.

What symptoms should prompt medical review?

Persistent abdominal pain, vomiting, inability to pass stool or gas, fever, wound redness, swelling, or unusual bleeding should be evaluated promptly. These symptoms may signal complications, but they are not necessarily caused by the surgical product.

FAQ: Hemostasis and Adhesion Prevention

Q: What is the difference between hemostasis and adhesion prevention?

A: Hemostasis means stopping bleeding during surgery. Adhesion prevention means reducing abnormal scar tissue between healing surfaces. They are related because bleeding can promote adhesion formation.

Q: Can an adhesion barrier replace surgical hemostasis?

A: No. A barrier is an adjunct, not a substitute. Major bleeding should first be controlled with sutures, cautery, pressure, or sealants, depending on the case.

Q: Are absorbable hemostatic products safe for patients?

A: Many absorbable products are designed for surgical use, but safety depends on the patient, site, infection risk, and product instructions. Surgeons should evaluate each case individually.

Q: Where can I learn more about Yishengtang intraoperative products?

A: You can review product information at www.sjzyst.com. Hospital procurement and clinical teams should still validate specifications, indications, and usage protocols before adoption.

This article was generated by AI and is for reference only.